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Malaria remains a major cause of morbidity and mortality 
throughout the world, with 32% of the world’s population 
living in areas of risk.1 Despite the progress that has been 
made in reducing the burden of malaria through improved 
access to preventive interventions,1 there remain many 
challenges to the eventual eradication of the parasite. 
Perhaps one of the greatest challenges is the continual 
battle with resistance, to both the drugs used to treat 
the cases and the insecticides used to kill the mosquito 
hosts.2,3 The former problem is particularly acute in the 
Greater Mekong region in southeast Asia where resistance 
to the key drug—artemisinin—is now widespread and 
partner drugs used in combination therapy are also 
beginning to fail.4 In response to this, a global concerted 
effort has been put in place to interrupt malaria 
transmission in the Greater Mekong region by 2025.5
Although the efficacy of vector control tools in 
reducing transmission is well established,6,7 the role of 
enhanced access to treatment is less well documented. 
In The Lancet, Jordi Landier and colleagues8 report one of 
the first systematic studies to assess the combined effect 
of a scaled up programme of increasing early diagnosis 
and treatment and targeted mass drug administration 
in four townships of eastern Myanmar on the incidence 
of Plasmodium falciparum  malaria. The programme 
was provided to all so-called malaria transmission 
hotspots (villages with >40% malaria of which 20% was 
P falciparum). Between May 1, 2014, and April 30, 2017, 
incidence of P falciparum malaria decreased by between 
60% and 98% and incidence of Plasmodium vivax malaria 
decreased by between 52% and 93% across the villages. 
Before the intervention, hotspot villages had a three-
times higher incidence of P falciparum at malaria posts 
than neighbouring villages (adjusted incidence rate ratio 
[IRR] 2·7, 95% CI 1·8–4·4). Early diagnosis and treatment 
was associated with a significant decrease in P falciparum 
incidence in hotspots (IRR 0·82, 95% CI 0·76–0·88 per 
quarter) and in other villages (0·75, 0·73–0·78 per quarter). 
Notably, the length of time that the village malaria post 
was established were associated with a decrease in malaria 
incidence, illustrating the importance of improving 
access to care in reducing local transmission. As would 
be expected, mass drug administration further reduced 
P falciparum incidence with an 80% reduction within 
hotspot villages (IRR 0·19, 95% CI 0·13–0·26). However, by 
contrast, there was no significant change in the incidence 
of P vivax malaria.
Because of the observational design of the study, 
there remain several unanswered questions. First, could 
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similar regional reductions be obtained with enhanced 
early diagnosis and treatment alone? Improving access 
to prompt diagnosis and treatment is a core aim of the 
WHO Global Technical Strategy for malaria.9 Despite 
this aim, access remains low in many of the areas with 
the highest malaria burden.10 Expansion of care through 
community-based approaches has been gaining traction 
for many years,11 with malaria diagnosis and treatment 
increasingly provided as part of an integrated community 
case management strategy for malaria, pneumonia, 
and diarrhoea. Strengthening existing health systems, 
which should also remain a priority, is likely to require 
a multifaceted approach to address issues with access, 
supply chain management, and quality of care across the 
public, private, and informal health-care sectors.12
Second, the definition of a hotspot and its role in 
sustaining transmission needs to be clarified. Landier and 
colleagues8 defined this on the basis of village prevalence 
of infection (using ultrasensitive diagnostic tests) 
compared with others in the same region—ultimately 
identifying spatial clusters of villages by testing within 
a 10 km radius of high-prevalence villages. Elsewhere, 
stratification of malaria interventions is often based 
on clinic-reported malaria incidence or prevalence of 
infection from household surveys, or both. However, 
local hotspots of infection have been shown to be both 
transient and metric dependent,13 and in a randomised 
controlled trial in the highlands of Kenya, targeting 
hotspots was not efficacious.14 Further research is 
therefore required to understand the broader use of this 
approach and the most appropriate geographical scale 
for intervention stratification.
Finally, the study targeted malaria hotspots using mass 
drug administration with treatment rounds given once 
per month for 3 months. Predictably, through clearing 
the reservoir of asymptomatic infection, this reduced 
the prevalence of infection, and additionally resulted in a 
reduction in malaria incidence in the following year. The 
effect of any transient intervention such as this can be 
predicted to decline over time;15 however, by temporarily 
reducing malaria incidence, the mass drug administration 
would have reduced the caseload for staff at the malaria 
posts, potentially enhancing the effect of early diagnosis 
and treatment. Undertaking mass drug administration 
on a large scale can be expensive, and hence its use needs 
to be compared with not only the health benefits and 
cost savings that are made through the direct reduction 
in malaria incidence but also the wider benefits that can 
be achieved if health-worker capacity is unlocked both in 
the community and in the broader health-care system. 
Further research to understanding this balance will help 
to determine the appropriateness of targeted mass drug 
administration as a tool to aid malaria elimination.
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